Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. No significant improvement has been reported with currently available systemic therapies. IFN-α has been tested in both clinic and animal models and only moderate benefits have been observed. In animal models, similar modest antitumor efficacy has also been reported for IFN-γ, a new type of IFN that acts through its own receptor complex. In the present study, the antitumor efficacy of the combination of IFN-α and IFN-γ was tested in the BNL mouse hepatoma model. This study was accomplished by using either engineered tumor cells (IFN-α/IFN-γ gene therapy) or by directly injecting tumor-bearing mice with IFN-α/IFN-γ. Both approaches demonstrated that IFN-α/ IFN-γ combination therapy was more efficacious than IFN monotherapy based on either IFN-α or IFN-γ. In complement to tumor surgery, IFN-α/IFN-γ combination induced complete tumor remission. Highest antitumor efficacy has been obtained following local administration of IFN-α/IFN-γ combination at the tumor site that was associated with strong NK cells tumor infiltration. This supports the use of IFN-α/IFN-γ combination as a new cancer immunotherapy for stimulating antitumor response after cancer surgery.
All Science Journal Classification (ASJC) codes
- Hepatocellular carcinoma
- IFN therapy
- IFN-α/IFN-γ combination
- Tumor immunity